Temporal development of muscle atrophy in murine model of arthritis is related to disease severity

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 3, 2013, Pages 231-238

  Filippin, Lidiane I ^a   Teixeira, Vivian N ^a   Viacava, Paula R ^a   Lora, Priscila S ^a   Xavier, Laura L ^a   Xavier, Ricardo M ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Arthritis animal model; Chronic inflammation; Muscle wasting

Indexed keywords

COLLAGEN; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; GASTROCNEMIUS MUSCLE; LOCOMOTION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKELETAL MUSCLE; TEMPORAL CORTEX;

EID: 84884574181     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0102-1     Document Type: Article

References (31)

1. Glass D, Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci. 2010;1211: 25-36.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358: 903-11.
3. da Rochal OM et al. Sarcopenia da caquexia reumatoide: conceituação, mecanismos, consequências clínicas e tratamentos possíveis. Rev Bras Reumatol. 2009;49: 288-301.
4. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91: 1123S-7.
5. Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull. 2010;95: 139-59.
6. Cruz-Jentoft AJ et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39: 412-23.
7. Cederholm TE et al. Toward a definition of sarcopenia. Clin Geriatr Med. 2011;27: 341-53.
8. Tracey KJ et al. Metabolic effects of cachectin tumor-necrosis-factor are modified by site of production-cachectin tumor necrosis factor-secreting tumor in skeletal-muscle induces chronic cachexia, while implantation in brain induces predominately acute anorexia. J Clin Invest. 1990;86: 2014-24.
9. Matschke V et al. Skeletal muscle properties in rheumatoid arthritis patients. Med Sci Sports Exerc. 2010;42: 2149-55.
10. Rall LC et al. The effect of progressive resistance training in rheumatoid arthritis. Increased strength without changes in energy balance or body composition. Arthritis Rheum. 1996;39: 415-26.
11. Granado M et al. Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J Endocrinol. 2006;191: 319-26.
12. Ozawa J et al. Morphological changes in hind limb muscles elicited by adjuvant-induced arthritis of the rat knee. Scand J Med Sci Sports. 2010;20: e72-9.
13. Hartog A, Hulsman J, Garssen J. Locomotion and muscle mass measures in a murine model of collagen-induced arthritis. BMC Musculoskeletal Disord. 2009;10: 59.
14. VDONT, Teixeira LIF, Viacava PR, Cerski MR, Xavier RM. Pathological and molecular changes in skeletal muscle of collagen induced arthritis. London: The European League Against Rheumatism; 2011.
15. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2: 1269-75.
16. Oliveira PG et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011;63: 2956-65.
17. Brietzke E et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116: 214-7.
18. Roubenoff R. Inflammatory and hormonal mediators of cachexia. J Nutr. 1997;127: 1014S-6.
19. Okiura T et al. Bone density of the femur and fiber cross-sectional area and oxidative enzyme activity of the tilbialis anterior muscle in type II collagen-induced arthritic mice. J Physiol Sci. 2008;58: 221-7.
20. Granado M et al. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288: E486-92.
21. Granado M et al. Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol Endocrinol Metab. 2007;292: E1656-65.
22. Castillero E et al. Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am J Physiol Endocrinol Metab. 2011;300: E790-9.
23. Balasubramaniam A et al. Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx. Am J Physiol Regul Integr Comp Physiol. 2009;296: R893-901.
24. Castillero E et al. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors. Am J Physiol Regul Integr Comp Physiol. 2009;297: R1322-31.
25. Acharyya S et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114: 370-8.
26. Llovera M et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998;142: 183-9.
27. Setoguchi C et al. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model. Mod Rheumatol. 2010;20: 381-8.
28. Lon HK et al. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm Res. 2011;28: 1622-30.
29. Braun TP et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med. 2011;208: 2449-63.
30. Roubenoff R et al. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum. 1997;40: 534-9.
31. Teixeira VD, Filippin LI, Xavier RM. Mechanisms of muscle wasting in sarcopenia. Rev Bras Reumatol. 2012;52: 252-9.